- Home
- COE vs IVA Comparison
COE vs IVA Comparison
Compare COE & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COE
- IVA
- Stock Information
- Founded
- COE 2011
- IVA 2011
- Country
- COE Singapore
- IVA France
- Employees
- COE N/A
- IVA N/A
- Industry
- COE Other Consumer Services
- IVA Biotechnology: Pharmaceutical Preparations
- Sector
- COE Real Estate
- IVA Health Care
- Exchange
- COE Nasdaq
- IVA Nasdaq
- Market Cap
- COE 115.0M
- IVA 127.0M
- IPO Year
- COE 2016
- IVA 2020
- Fundamental
- Price
- COE $19.78
- IVA $2.84
- Analyst Decision
- COE
- IVA Strong Buy
- Analyst Count
- COE 0
- IVA 4
- Target Price
- COE N/A
- IVA $13.25
- AVG Volume (30 Days)
- COE 19.2K
- IVA 10.9K
- Earning Date
- COE 03-21-2025
- IVA 03-26-2025
- Dividend Yield
- COE N/A
- IVA N/A
- EPS Growth
- COE N/A
- IVA N/A
- EPS
- COE N/A
- IVA N/A
- Revenue
- COE $41,924,000.00
- IVA $20,652,523.00
- Revenue This Year
- COE N/A
- IVA N/A
- Revenue Next Year
- COE N/A
- IVA $197.46
- P/E Ratio
- COE N/A
- IVA N/A
- Revenue Growth
- COE 69.79
- IVA N/A
- 52 Week Low
- COE $6.00
- IVA $1.53
- 52 Week High
- COE $25.70
- IVA $4.50
- Technical
- Relative Strength Index (RSI)
- COE 45.81
- IVA 69.74
- Support Level
- COE $19.55
- IVA $2.58
- Resistance Level
- COE $25.70
- IVA $2.80
- Average True Range (ATR)
- COE 1.57
- IVA 0.15
- MACD
- COE -0.34
- IVA 0.04
- Stochastic Oscillator
- COE 8.36
- IVA 81.31
About COE 51Talk Online Education Group
51 Talk Online Education Group is an online education platform in China, with core expertise in English education. The company's mission is to make quality education accessible and affordable. It's online and mobile education platforms enable students across China to take live interactive English lessons with overseas foreign teachers, on demand.
About IVA Inventiva S.A. American Depository Shares
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.